blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2755973

EP2755973 - SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.09.2016
Database last updated on 31.08.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
SANOFI
54, rue La Boétie
75008 Paris / FR
[2014/30]
Inventor(s)01 / BIALY, Laurent
Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
02 / LORENZ, Katrin
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
03 / WIRTH, Klaus
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
04 / STEINMEYER, Klaus
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
05 / HESSLER, Gerhard
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
06 / PERNERSTORFER, Josef
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
07 / BRENDEL, Joachim
c/o Sanofi-Aventis Deutschland GmbH
Industriepark Hoechst
65926 Frankfurt am Main / DE
 [2014/30]
Representative(s)Venne-Dunker, Sabine
Sanofi-Aventis Deutschland GmbH
Global Intellectual Property Department
Industriepark Höchst
Gebäude K 703
65926 Frankfurt am Main / DE
[2014/30]
Application number, filing date11757858.316.09.2011
[2015/45]
WO2011EP66061
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013037415
Date:21.03.2013
Language:EN
[2013/12]
Type: A1 Application with search report 
No.:EP2755973
Date:23.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 21.03.2013 takes the place of the publication of the European patent application.
[2014/30]
Type: B1 Patent specification 
No.:EP2755973
Date:04.11.2015
Language:EN
[2015/45]
Search report(s)International search report - published on:EP21.03.2013
ClassificationIPC:C07D471/04, C07D471/18, A61K31/437, A61K31/439, A61P9/06
[2014/30]
CPC:
C07D471/04 (EP,CN,US); A61P11/00 (EP); A61P11/16 (EP);
A61P25/00 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/06 (EP); C07D471/18 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/30]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SUBSTITUIERTE 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE, IHRE VERWENDUNG ALS MEDIKAMENT UND PHARMAZEUTISCHE PRÄPARATE DAMIT[2014/30]
English:SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM[2014/30]
French:4,5,6,7-TÉTRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES SUBSTITUÉES, LEUR UTILISATION EN TANT QUE MÉDICAMENT ET PRÉPARATIONS PHARMACEUTIQUES LES COMPRENANT[2014/30]
Entry into regional phase16.04.2014National basic fee paid 
16.04.2014Designation fee(s) paid 
16.04.2014Examination fee paid 
Examination procedure16.04.2014Examination requested  [2014/30]
12.11.2014Amendment by applicant (claims and/or description)
18.05.2015Communication of intention to grant the patent
21.09.2015Fee for grant paid
21.09.2015Fee for publishing/printing paid
21.09.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.05.2015
Opposition(s)05.08.2016No opposition filed within time limit [2016/41]
Fees paidRenewal fee
28.02.2014Renewal fee patent year 03
12.09.2014Renewal fee patent year 04
11.09.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL04.11.2015
MK04.11.2015
RS04.11.2015
SM04.11.2015
NO04.02.2016
IS04.03.2016
[2018/46]
Former [2018/31]MK04.11.2015
RS04.11.2015
SM04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/38]RS04.11.2015
SM04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/27]RS04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/25]LV04.11.2015
RS04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/23]RS04.11.2015
NO04.02.2016
IS04.03.2016
Former [2016/22]NO04.02.2016
IS04.03.2016
Former [2016/21]NO04.02.2016
Cited inInternational search[AD]US4500525  (WINTERS GIORGIO [IT], et al) [AD] 1-19 * claim 1 *;
 [AD]US2008188477  (BRENDEL JOACHIM [DE], et al) [AD] 1-19 * claims 1, 10-12 * * page 2, paragraph [0018] *;
 [E]WO2011115804  (IRONWOOD PHARMACEUTICALS INC [US], et al) [E] 1,5,16,19 * page 31 - page 32; compounds I-38, I-40, I50, I-51, I-52 * * page 33; compounds I-54, I-55, I-56, I-57, I-58, I-63 ** page 61 - page 62, paragraph [0186]; claim 1 *;
 [A]  - WINTERS G ET AL, "Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19850101), vol. 28, doi:10.1021/JM00145A015, ISSN 0022-2623, pages 934 - 940, XP002256019 [A] 1-19 * page 935; table 1; compounds 22, 25 *

DOI:   http://dx.doi.org/10.1021/jm00145a015
by applicantEP0086422
 WO2005016965
 WO2006136304
 WO2007124849
    - COETZEE W.J. ET AL., "Molecular diversity of K+ channels", ANN. NEW YORK ACAD. SCI., (1999), pages 233 - 285
    - D.A. BAYLISS, P. BARRETT, TRENDS IN PHARMACOLOGICAL SCIENCES, (2008), vol. 29, no. 11, pages 566 - 575
    - BERG AP., TALLEY E.M., MANGER J.P., BAYLISS D.A., "Motoneurons express Heteromeric TWIK-related acid-sensitive K+ (TASK) Channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits", J. NEUROSCIENCE, (2004), pages 6693 - 6702
    - DUPRAT F., LESAGE F., FINK M., REYES R., HEURTEAUX C., LAZDUNSKI M, "TASK, a human background K+ channel to sense external pH variations near physiological pH", EMBO J., (1997), pages 5464 - 5471
    - PATEL A.J., HONORE E., "Properties and modulation of mammalian 2P domain K+ channels", TRENDS NEUROSCI., (2001), doi:doi:10.1016/S0166-2236(00)01810-5, pages 339 - 346, XP004239821

DOI:   http://dx.doi.org/10.1016/S0166-2236(00)01810-5
    - JOURNAL OF NEUROSCIENCE, (2005), vol. 25, no. 49, pages 11455 - 11467
    - MEDHURST A.D., RENNIE G., CHAPMAN C.G., MEADOWS H., DUCKWORTH M.D, KELSELL R.E., GLOBER 1.1., PANGALOS M.N., "Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery", MOL. BRAIN RES., (2001), doi:doi:10.1016/S0169-328X(00)00263-1, pages 101 - 114, XP002329245

DOI:   http://dx.doi.org/10.1016/S0169-328X(00)00263-1
    - BUCKLER K.J., WILLIAMS B.A., HONORE E., "An oxygen-, acid-and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells", J. PHYSIOL., (2000), pages 135 - 142
    - BAYLISS D.A., TALLEY E.M., SIROIS J.E., LEI Q., "TASK-1 is a highly modulated pH-sensitive 'leak' K+ channel expressed in brainstem respiratory neurons", RESPIRATION PHYSIOLOGY, (2001), pages 159 - 174
    - LAURITZEN , ZANZOURI M., HONORE E., DUPRAT F., EHRENGRUBER M.U., LAZDUNSKI M., PATEL A.J., "K+- dependent cerebellar granule neuron apoptosis - Role of Task leak K+ channels", J. BIOL. CHEM., (2003), pages 32068 - 32076
    - PATEL A.J., LAZDUNSKI M., "The 2P-domain K+ channels: role in apoptosis and tumorigenesis", PFLUGERS ARCH., (2004), doi:doi:10.1007/s00424-004-1255-8, pages 261 - 273, XP002329247

DOI:   http://dx.doi.org/10.1007/s00424-004-1255-8
    - BITTNER STEFAN, MEUTH SVEN G, GOBEL KERSTIN, MELZER NICO, HERRMANN ALEXANDER M, SIMON OLE J, WEISHAUPT ANDREAS, BUDDE THOMAS, BAYL, BRAIN : A JOURNAL OF NEUROLOGY, (2009), vol. 132, pages 2501 - 16
    - BASIC RES CARDIOL., (201101), vol. 106, no. 1, pages 75 - 87
    - PUTZKE C, WEMHONER K, SACHSE FB, RINNE S, SCHLICHTHORL G, LI XT, JAE L, ECKHARDT I, WISCHMEYER E, WULF H, CARDIOVASCULAR RESEARCH, (2007), vol. 75, pages 59 - 68
    - OURNAL OF CLINICAL INVEST., (2011), vol. 121, no. 8, pages 2955 - 2968
    - T. J. COLATSKY ET AL., "Potassium channels as targets for antiarrhythmic drug action", DRUG DEV. RES., (1990), vol. 19, pages 129 - 140
    - D. M. RODEN, "Current status of class III antiarrhythmic drug therapy", AM. J. CARDIOL., (1993), vol. 72, pages 44B - 49B
    - BASIC. RES. CARDIOL., (2003), vol. 98, pages 137 - 148
    - JACC, (2001), vol. 37, no. 3
    - JOURNAL OF MOLECULAR MEDICINE, (2004), pages 308 - 316
    - EUROPEAN JOURNAL OF PHYSIOLOGY, (2005), vol. 450, pages 201 - 208
    - PATEL A.J., HONORE E., LESAGE F., FINK M., ROMEY G., LAZDUNSKI M, "Inhalational anesthetics activate two-pore-domain background K+ channels", NATURE NEUROSCI., (1999), doi:doi:10.1038/8084, pages 422 - 426, XP002145560

DOI:   http://dx.doi.org/10.1038/8084
    - PEUKERT, S., BRENDEL, J., PIRARD, B., BRUEGGEMANN, A., BELOW, P., KLEEMANN, H.-W., HEMMERLE, H., SCHMIDT, W., "Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5.", JOURNAL OF MEDICINAL CHEMISTRY, (2003), vol. 46, no. 4, doi:doi:10.1021/jm0210461, pages 486 - 498, XP002292322

DOI:   http://dx.doi.org/10.1021/jm0210461
    - STREIT, A. K., NETTER, M. F., KEMPF, F., WALECKI, M., RINNE, S., BOLLEPALLI, M. K., PREISIG-MUELLER, R., RENIGUNTA, V., DAUT, J.,, "A Specific Two-pore Domain Potassium Channel Blocker Defines the Structure of the TASK-1 Open Pore", JOURNAL OF BIOLOGICAL CHEMISTRY, (2011), vol. 286, no. 16, pages 13977 - 13984
    - MAINGRET F., PATEL A.J., LAZDUNSKI M., HONORE E., "The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1", EMBO J., (2001), doi:doi:10.1093/emboj/20.1.47, pages 47 - 54, XP001203548

DOI:   http://dx.doi.org/10.1093/emboj/20.1.47
    - COTTEN J.F., KESHAVAPRASAD B, LASTER M.J., EGER E.I., YOST C.S., "The Ventilatory Stimulant Doxapram Inhibits TASK Tandem Pore (K2p) Potassium Channel Function but Does Not Affect Minimum Alveolar Anesthetic Concentration", ANESTH. ANALG., (2006), doi:doi:10.1213/01.ane.0000194289.34345.63, pages 779 - 785, XP009103929

DOI:   http://dx.doi.org/10.1213/01.ane.0000194289.34345.63
    - DALISAY, D. S., QUACH, T., NICHOLAS, G. N., MOLINSKI, T. F., ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, (2009), vol. 48, pages 4367 - 4371
    - NOZAKI, S., J. PEPTIDE RES., (1999), vol. 54, page 162
    - KNORR, R. ET AL., TETRAHEDRON LETT., (1989), vol. 30, page 1927
    - ALTERMAN, M., ANDERS, H., JOURNAL OF ORGANIC CHEMISTRY, (2000), vol. 65, no. 23, pages 7984 - 7989
    - KNOBLOCH ET AL., NAUNYN-SCHMIEDBERG'S ARCH. PHARMACOL., (2002), vol. 366, pages 482 - 487
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.